Apixaban: A novel oral inhibitor of factor Xa

American Journal of Health-System Pharmacy

Volumn 69, Issue 13, 2012, Pages 1113-1126

  Nutescu, Edith ^a,b  

^a Department of Pharmacy Practice   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTITHROMBOCYTIC AGENT; APIXABAN; BLOOD CLOTTING FACTOR 9; CARBAMAZEPINE; CLARITHROMYCIN; D DIMER; DABIGATRAN; DABIGATRAN ETEXILATE; DILTIAZEM; ENOXAPARIN; FONDAPARINUX; HEPARIN; HYPERICUM PERFORATUM EXTRACT; ITRACONAZOLE; KETOCONAZOLE; LIVER ENZYME; LOW MOLECULAR WEIGHT HEPARIN; NAPROXEN; PHENOBARBITAL; PHENYTOIN; POSACONAZOLE; PROTHROMBIN; RIFAMPICIN; RITONAVIR; RIVAROXABAN; UNINDEXED DRUG; VORICONAZOLE; WARFARIN;

ACUTE CORONARY SYNDROME; AREA UNDER THE CURVE; BLEEDING; BRAIN HEMORRHAGE; DRUG ACCUMULATION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; HALF LIFE TIME; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; MONOTHERAPY; ORTHOPEDIC SURGERY; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SINGLE DRUG DOSE; STROKE; THROMBOCYTOPENIA; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 84862894480     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp110418     Document Type: Review

References (111)

1. Oger E, for the EPI-GETBP Study Group. Incidence of venous thromboembolism: a community-based study in Western France. Thromb Haemost. 2000; 83:657-60.
2. Spencer FA, Emery C, Lessard D et al. The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med. 2006; 21:722-7. (Pubitemid 43973557)
3. Lee CH, Cheng CL, Lin LJ et al. Epidemiology and predictors of short-term mortality in symptomatic venous thromboembolism. Circ J. 2011; 75:1998-2004.
4. Lloyd-Jones D, Adams RJ, Brown TM et al. Executive summary: heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation. 2010; 121:948-54. [Erratum, Circulation. 2010; 121:e259.]
5. Iwahana H, Ishikawa S, Ishikawa J et al. Atrial fibrillation is a major risk factor for stroke, especially in women: the Jichi Medical School cohort study. J Epidemiol. 2011; 21:95-101.
6. Joffe HV, Goldhaber SZ. Upperextremity deep vein thrombosis. Circulation. 2002; 106:1874-80.
7. Weitz JI. New oral anticoagulants in development. Thromb Haemost. 2010; 103:62-70.
8. Garcia D, Libby E, Crowther MA. The new oral anticoagulants. Blood. 2010; 115:15-20.
9. Gross PL, Weitz JI. New anticoagulants for treatment of venous thromboembolism. Arterioscler Thromb Vasc Biol. 2008; 28:380-6.
10. Boulanger L, Kim J, Friedman M et al. Patterns of use of antithrombotic therapy and quality of anticoagulation among patients with non-valvular atrial fibrillation in clinical practice. Int J Clin Pract. 2006; 60:258-64. (Pubitemid 43337604)
11. Schuringa P, Yen D. Home prophylactic warfarin anticoagulation program after hip and knee arthroplasty. Can J Surg. 1999; 42:360-2. (Pubitemid 29479811)
12. Sunderji R, Gin K, Shalansky K et al. A randomized trial of patient self-managed versus physician-managed oral anticoagulation. Can J Cardiol. 2004; 20:1117-23. (Pubitemid 39302738)
13. Gallus AS, Baker RI, Chong BH et al. Consensus guidelines for warfarin therapy. Recommendations from the Australasian Society of Thrombosis and Haemostasis. Med J Aust. 2000; 172:600-5. (Pubitemid 30438937)
14. Fang MC, Chang Y, Hylek EM et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med. 2004; 141:745-52.
15. Connolly SJ, Pogue J, Eikelboom J et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation. 2008; 118:2029-37.
16. Caprini JA, Arcelus JI, Motykie G et al. The influence of oral anticoagulation therapy on deep vein thrombosis rates four weeks after total hip replacement. J Vasc Surg. 1999; 30:813-20. (Pubitemid 29534178)
17. Electronic Medicines Compendium. Pradaxa: summary of product characteristics. www.medicines.org.uk/emc/medicine/20760 (accessed 2011 May 6).
18. Electronic Medicines Compendium. Xarelto: summary of product characteristics. www.medicines.org.uk/emc/medicine/21265 (accessed 2011 May 6).
19. Pradaxa (dabigatran etexilate) prescribing information. Ridgefield, CT: Boehringer Ingelheim; 2010.
20. Food and Drug Administration. FDA approves Xarelto to prevent stroke in people with common type of abnormal heart rhythm. www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ucm278646.htm (accessed 2012 Apr 23).
21. European Medications Agency. Eliquis (apixaban). www.ema.europa.eu/ docs/en-GB/document-librar y/EPAR---Summary-for-the-public/human/002148/ WC500107773.pdf (accessed 2011 Sep 9).
22. TheRubins.com. Exanta, the blood thinner is withdrawn from the market. www.therubins.com/ideas/exanta.htm (accessed 2011 Sep 19).
23. Pinto DJ, Orwat MJ, Koch S et al. Discovery of 1-(4-methoxyphenyl)-7-oxo- 6-(4-(2-oxopiperidin-1-yl)phenyl)- 4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c] pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem. 2007; 50:5339-56. (Pubitemid 350057846)
24. Jiang X, Crain EJ, Luettgen JM et al. Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro. Thromb Haemost. 2009; 101:780-2.
25. Wong PC, Crain EJ, Xin B et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost. 2008; 6:820-9. (Pubitemid 351524543)
26. Wong PC, Crain EJ, Watson CA et al. Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits. J Thromb Haemost. 2009; 7:1313-20.
27. Wong PC, Watson CA, Crain EJ. Arterial antithrombotic and bleeding time effects of apixaban, a direct factor Xa inhibitor, in combination with antiplatelet therapy in rabbits. J Thromb Haemost. 2008; 6:1736-41.
28. Barrett YC, Wang Z, Frost C et al. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost. 2010; 104:1263-71.
29. Van Ryn J, Stangier J, Haertter S et al. Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010; 103:1116-27.
30. Raghavan N, Frost CE, Yu Z et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos. 2009; 37:74-81.
31. Frost C, Yu Z, Moore K et al. Apixaban, an oral direct factor Xa inhibitor: multiple-dose safety, pharmacokinetics, and pharmacodynamics in healthy subjects. J Thromb Haemost. 2007; 5(suppl 2). Abstract.
32. Zhang D, He K, Raghavan N et al. Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans. Drug Metab Dispos. 2009; 37:1738-48.
33. Wang L, Zhang D, Raghavan N et al. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos. 2010; 38:448-58.
34. Frost C, Yu Z, Shenker A et al. Food does not affect the pharmacokinetics of apixaban, an oral, factor Xa inhibitor. Can J Clin Pharmacol. 2008; 15:e469. Abstract.
35. Yamahira N, Imail Y, Yu Z et al. A placebo-controlled, ascending multiple-dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of apixaban in Japanese healthy adult male subjects. Can J Clin Pharmacol. 2008; 15:e719. Abstract.
36. Yu Z, Nepal S, Gragat A et al. Single dose apixaban pharmacokinetics and pharmacodynamics in healthy male Japanese and Caucasian subjects. Can J Clin Pharmacol. 2008; 15:e724. Abstract.
37. Song Y, Cui Y, Li T et al. Apixaban pharmacokinetics and pharmacodynamics in healthy Chinese subjects. J Clin Pharmacol. 2010; 50:1062. Abstract.
38. Frost CE, Yu Z, Wang J et al. Single-dose safety and pharmacokinetics of apixaban in subjects with mild or moderate hepatic impairment. Clin Pharmacol Ther. 2009; 85(suppl 1):S34. Abstract.
39. Frost CE, Nepal S, Barrett YC et al. Effects of age and gender on the singledose pharmacokinetics (PK) and pharmacodynamics (PD) of apixaban. J Thromb Haemost. 2009; 7(suppl 2): PP-MO-407. Abstract.
40. Bristol-Myers Squibb. Eliquis: summary of product characteristics. www.eliquis.com/PDF/ELIQUIS%20%C2%AE%20%28apixaban%29%20SmPC.pdf (accessed 2011 Sep 9).
41. Barrett YC, Li T, Wang J et al. Assessment of pharmacokinetic and pharmacodynamic interaction between apixaban and enoxaparin in healthy subjects. Pathophysiol Haemost Thromb. 2009; 37(suppl 1):226. Abstract.
42. Alexander JH, Becker RC, Bhatt DL et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation. 2009; 119:2877-85.
43. Frost C, Wang J, Nepal S et al. Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. J Clin Pharmacol. 2009; 49:1091-1130. Abstract.
44. Vakkalagadda B, Frost C, Wang J et al. Effect of rifampin on the pharmacokinetics of apixaban, an oral direct inhibitor of factor Xa. J Clin Pharmacol. 2009; 49:1124. Abstract.
45. Frost C, Lee L, Li LY et al. Apixaban does not affect the pharmacokinetics of digoxin. J Clin Pharmacol. 2007; 47:1196. Abstract.
46. Upreti VV, Song Y, Wang J et al. Effect of famotidine on the pharmacokinetics of apixaban, an oral direct inhibitor of factor Xa, in healthy subjects. J Clin Pharmacol. 2009; 49:1117. Abstract.
47. Lassen MR, Davidson BL, Gallus A et al. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost. 2007; 5:2368-75. (Pubitemid 350154345)
48. Leil TA, Feng Y, Zhang L et al. Quantification of apixaban's therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose. Clin Pharmacol Ther. 2010; 88:375-82.
49. Lassen MR, Raskob GE, Gallus A et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009; 361:594-604.
50. Lassen MR, Raskob GE, Gallus A et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010; 375:807-15.
51. Lassen MR, Gallus A, Raskob GE et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010; 363:2487-98.
52. Cohen AT, Tapson VF, Bergmann JF et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet. 2008; 371:387-94. (Pubitemid 351173321)
53. Barba R, Zapatero A, Losa JE et al. Venous thromboembolism in acutely ill hospitalized medical patients. Thromb Res. 2010; 126:276-9.
54. Geerts WH, Bergqvist D, Pineo GF et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008; 133(suppl):381S-453S. (Pubitemid 351894916)
55. Hull RD, Schellong SM, Tapson VF et al. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med. 2010; 153:8-18.
56. Goldhaber SZ, Leizorovicz A, Kakkar AK et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med. 2011; 365:2167-77.
57. ClinicalTrials.gov. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. www.clinicaltrials.gov/ ct2/show/NCT00643201 (accessed 2010 Dec 21).
58. ClinicalTrials.gov. Efficacy and safety study of apixaban for extended treatment of deep vein thrombosis or pulmonary embolism. www.clinicaltrials.gov/ ct2/show/NCT00633893 (accessed 2010 Dec 21).
59. ClinicalTrials.gov. A phase III study of apixaban in patients with atrial fibrillation (AVERROES). www.clinicaltrials.gov/ct2/show/NCT00496769 (accessed 2010 Dec 21).
60. ClinicalTrials.gov. Apixaban for the prevention of stroke in subjects with atrial fibrillation (ARISTOTLE). www.clinicaltrials.gov/ct2/show/ NCT00412984 (accessed 2010 Dec 21).
61. Granger CB, Alexander JH, McMurray JJ et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365:981-92.
62. ClinicalTrials.gov. Phase III acute coronary syndrome (APPRAISE-2). www.clinicaltrials.gov/ct2/show/NCT00831441 (accessed 2010 Dec 21).
63. Kearon C, Kahn SR, Agnelli G et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008; 133(suppl):454S-545S. (Pubitemid 351892971)
64. Buller H, Deitchman D, Prins M et al. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost. 2008; 6:1313-8. (Pubitemid 352016310)
65. Food and Drug Administration. FDA approves Pradaxa to prevent stroke in people with atrial fibrillation. www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm230241.htm (accessed 2011 Sep 9).
66. Patrono C, Rocca B. Aspirin: promise and resistance in the new millennium. Arterioscler Thromb Vasc Biol. 2008; 28:s25-32.
67. Fuster V, Ryden LE, Cannom DS et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace. 2006; 8:651-745. (Pubitemid 44472247)
68. Eikelboom JW, O'Donnell M, Yusuf S et al. Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. Am Heart J. 2010; 159:348-53.
69. Connolly SJ, Eikelboom J, Joyner C et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011; 364:806-17.
70. Lopes RD, Alexander JH, Al Khatib SM et al. Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J. 2010; 159:331-9.
71. Eikelboom JW, Hirsh J. Combined antiplatelet and anticoagulant therapy: clinical benefits and risks. J Thromb Haemost. 2007; 5(suppl 1):255-63.
72. Paikin JS, Wright DS, Eikelboom JW. Effectiveness and safety of combined antiplatelet and anticoagulant therapy: a critical review of the evidence from randomized controlled trials. Blood Rev. 2011; 25:123-9.
73. Alexander JH, Lopes RD, James S et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011; 365:699-708.
74. Becker RC, Alexander JH, Newby LK et al. Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome. Thromb Haemost. 2010; 104:976-83.
75. Kubitza D, Becka M, Wensing G et al. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 - an oral, direct factor Xa inhibitor - after multiple dosing in healthy male subjects. Eur J Clin Pharmacol. 2005; 61:873-80. (Pubitemid 41803696)
76. Kubitza D, Becka M, Roth A et al. Doseescalation study of the pharmacokineticsand pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin. 2008; 24:2757-65.
77. Stangier J, Rathgen K, Stahle H et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007; 64:292-303. (Pubitemid 47283865)
78. Stangier J, Stahle H, Rathgen K et al. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet. 2008; 47:47-59. (Pubitemid 350260888)
79. Weinz C, Schwarz T, Kubitza D et al. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metab Dispos. 2009; 37:1056-64.
80. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet. 2009; 48:1-22.
81. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361:1139-51.
82. Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365:883-91.
83. Frost C, Song Y, Barrett YC et al. Direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban. J Thromb Haemost. 2011; 9(suppl 2):569. Abstract.
84. Xarelto (rivaroxaban) prescribing information. Leverkusen, Germany: Bayer; 2011.
85. Turpie AG, Lassen MR, Davidson BL et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009; 373:1673-80.
86. Lassen MR, Ageno W, Borris LC et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008; 358: 2776-86. (Pubitemid 351930852)
87. Kakkar AK, Brenner B, Dahl OE et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008; 372:31-9.
88. Eriksson BI, Borris LC, Friedman RJ et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008; 358:2765-75. (Pubitemid 351930851)
89. Eriksson BI, Kakkar AK, Turpie AG et al. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. J Bone Joint Surg Br. 2009; 91:636-44.
90. Trkulja V, Kolundzic R. Rivaroxaban vs dabigatran for thromboprophylaxis after joint-replacement surgery: exploratory indirect comparison based on meta-analysis of pivotal clinical trials. Croat Med J. 2010; 51:113-23.
91. Huisman MV, Quinlan DJ, Dahl OE et al. Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: results of separate pooled analyses of phase III multicenter randomized trials. Circ Cardiovasc Qual Outcomes. 2010; 3:52-60.
92. Ginsberg JS, Davidson BL, Comp PC et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009; 24:1-9.
93. Eriksson BI, Dahl OE, Rosencher N et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007; 370:949-56. (Pubitemid 47393577)
94. Huo M, Eriksson B, Dahl O et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty: the RE-NOVATE II randomised trial. Paper presented at the Annual Congress of the European Haematology Association. Barcelona, Spain; 2010 Jun 12.
95. Eriksson BI, Dahl OE, Rosencher N et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007; 5:2178-85. (Pubitemid 47617868)
96. Wolowacz SE, Roskell NS, Plumb JM et al. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb Haemost. 2009; 101:77-85.
97. ROCKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J. 2010; 159:340-7.
98. Mahaffey K, Fox KA, on behalf of the ROCKET AF Investigators. Stroke prevention using the oral direct factor Xa inhibitor rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation. Paper presented at the American Heart Association Scientific Sessions 2010. Chicago, IL; 2010 Nov 13.
99. Albers GW, Diener HC, Frison L et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA. 2005; 293:690-8.
100. Olsson SB. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet. 2003; 362:1691-8. (Pubitemid 37468318)
101. Buller HR. Once-daily oral rivaroxaban versus placebo in the long-term prevention of recurrent symptomatic venous thromboembolism. The EINSTEIN-Extension Study. http://ash.confex.com/ash/2009/webprogram/Paper25669. html (accessed 2010 Dec 21).
102. Schulman S, Kearon C, Kakkar AK et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009; 361:2342-52.
103. Connolly S, Pogue J, Hart R et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006; 367:1903-12.
104. Singer DE, Albers GW, Dalen JE et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008; 133(6 suppl):546S-92S. (Pubitemid 351892972)
105. Mega JL, Braunwald E, Mohanavelu S et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet. 2009; 374:29-38.
106. Gibson CM, Mega JL, Burton P et al. Rationale and design of the anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndromethrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome. Am Heart J. 2011; 161:815-21.
107. Agnelli G, Gallus A, Goldhaber SZ et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study. Circulation. 2007; 116:180-7. (Pubitemid 47057524)
108. Buller HR, Lensing AW, Prins MH et al. A dose-ranging study evaluating oncedaily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood. 2008; 112:2242-7.
109. Bauersachs R, Berkowitz SD, Brenner B et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010; 363:2499-510.
110. Cohen AT, Spiro TE, Buller HR et al. Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. J Thromb Thrombolysis. 2011; 31:407-16.
111. ABC News. FDA panel endorses Xarelto for stroke prevention. http://abcnews.go.com/Health/fda-panel-endorses-xarelto-stroke-prevention/story? id=14483537 (accessed 2011 Sep 19).